Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to share news the company has announced it has acquired certain U.S. and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics. The company holds a portfolio of FDA cleared dental and medical devices.
Huntsman telling Proactive, the expansion of its portfolio has revenue potential including the flagship FDA cleared product, Pod or Preventive Oral Device .
That device is designed for help with teeth grinding and Temporomandibular Joint Dysfunctions. An estimated 40 million patients in the U.S. and Canada suffer from these conditions.
Huntsman also shared now gives the company a complete line of lower cost products with higher margins to sit alongside its existing Vivos Method treatments.
#proactiveinvestors #vivostherapeuticsinc #nasdaq #vvos #biopharma
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
